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ABSTRACT 
 
INTRODUCTION: CYP3A subfamily of enzymes is involved in the metabolism of more 
than 50% of all currently used drugs in humans. Clinically most important CYP3A enzymes 
are CYP3A4 and CYP3A5. CYP3A5 is polymorphically expressed at approximately 20% of 
individuals and it shows overlapping substrate specificity with CYP3A4, but the extent of 
known CYP3A4 substrates metabolized by CYP3A5 at individuals polymorphically 
expressing it, is under investigation. In vitro studies using recombinant systems are 
extensively applied to predict pharmacokinetic properties of drugs in vivo, where enzyme 
kinetic parameters from the in vitro experiments are extrapolated to in vivo values. 
 
AIM: Establishment of a stable THLE cell line specifically expressing human CYP3A5 
enzymes was one of the aims of the present thesis. Another aim was to investigate and 
compare metabolism of midazolam, which is a standard in vitro probe for characterization of 
the CYP3A activity, in different in vitro systems expressing human CYP3A5 enzymes.  
 
METHODS: Stable transfection of THLE cells with a DNA coding for human CYP3A5 was 
performed in order to obtain human cell line specifically expressing CYP3A5 enzymes. The 
metabolism studies of midazolam by CYP3A5 were performed in two in vitro systems: 
microsomes isolated from baculovirus infected insect cells specifically expressing human 
CYP3A5 enzymes (Supersomes®), the difference between the two preparations applied being 
coexpression of cytochrome b5 in only one of them.  
 
RESULTS: The transfection of THLE cells with human DNA coding for CYP3A5 enzymes 
was achieved, but the cells did not express functional CYP3A5 proteins, which resulted in no 
metabolite formation after incubation with midazolam. The formation of the main metabolite 
of midazolam, 1′-hydroxy-midazolam (1′-OH-MDZ), followed Michaelis-Menten like 
kinetics in Supersomes® with coexpressed cytochrome b5, while the formation of the same 
metabolite in the Supersomes® without cytochrome b5 demonstrated substrate inhibition. 
Surprisingly, the formation rate of 1′-OH-MDZ appeared to be higher in the Supersomes® 
without cytochrome b5. Formation of the minor metabolite of midazolam, 4-hydroxy-
midazolam (4-OH-MDZ), had sigmoid shape independently of the presence of cytochrome b5, 
but the formation rate was lower in the Supersomes® with coexpressed cytochrome b5. 
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CONCLUSION: Cytochrome b5 appears to have an impact on midazolam metabolism 
catalyzed by CYP3A5 in vitro. For further evaluation, more experiments are necessary, and 
the conditions need to be optimalized in order to obtain functional CYP3A5 proteins from the 
THLE cells, so that the comparisons of the CYP3A5 catalyzed metabolism of midazolam 
between insect and human microsomes can be performed. 
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1 INTRODUCTION 
  
1.1 METABOLISM 
Pharmacological effects of drugs rely on their ability to pass biological membranes, access 
site of action and interact with target cells, creating a response. Concentration of a drug at the 
site of action is determined by its absorption, distribution, metabolism and excretion 
(pharmacokinetics). In order to be excreted from the body, lipophilic characteristics of drugs, 
promoting their passage through membranes, have to be transformed to more hydrophilic 
ones. This is achieved by a series of biotransformations, often classified as either phase I or 
phase II reactions. In phase I reactions, functional groups are either exposed on, or introduced 
to the parent compound. In phase II reactions, polar groups (glucuronic acid, sulphate, 
glutathione, amino acids or acetate) are coupled to the parent compound, increasing their 
water solubility and promoting excretion. 
 
1.2 CYTOCHROME P450 MONOOXYGENASE SYSTEM (CYP 450) 
Cytochrome P450 (CYP) enzymes are classified as phase I enzymes and they play a major 
role in the oxidative metabolism of many structurally different xenobiotics (drugs, chemicals), 
as well as endobiotics (steroids, fatty acids, prostaglandins) [1]. CYP enzymes are heme 
containing proteins bound to membrane of endoplasmatic reticulum (ER), where they are also 
associated with nicotinamide adenine dinucleotide phosphate (NADPH) cytochrome 
reductase (Figure 1), required for oxidative activity of CYP enzymes. NADPH - cytochrome 
reductase is present in a ratio of about ten cytochrome P450 molecules per one reductase. 
Other cofactors involved in metabolic oxidation catalyzed by CYP enzymes are NADPH, 
molecular oxygen (O2) and sometimes cytochrome b5 [1]. CYP enzymes are primarily 
expressed in hepatic tissue, but they are also present in extrahepatic tissues, such as 
gastrointestinal tract, kidney, lung and the placenta [2]. 
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Figure 1: Cytochrome P450 (CYP) hemoprotein in the lipid bilayer of ER. Most part of the CYP enzyme is on 
the cytosolic surface of ER. The substrate (i.e. drug) often has hydrophobic properties and is dissolved in the 
membrane [3]. 
 
The process of oxidative metabolism of a drug is shown schematically in Figure 2. The drug 
(D-H) reacts with the oxidized form of the CYP enzyme (CYP-Fe3+), forming a drug-enzyme 
complex (CYP-Fe3+-D-H). Cytochrome P450 reductase transfers one electron from NADPH 
to the CYP-Fe3+-D-H complex, reducing it to CYP-Fe2+-D-H, which in turn, reacts with 
molecular O2, followed by transfer of a second electron from NADPH. Finally, one atom of 
O2 is released as H2O and the second atom is transferred to the substrate. In some oxidation 
reactions catalyzed by CYP3A enzymes, cytochrome b5 has been shown to support the 
electron transfer from NADPH to CYP3A via the reductase.  In that case, the second of the 
two electrons donated to the CYP (Figure 2), is coming from cytochrome b5 [4].    
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Figure 2: Oxidative metabolism of a drug (D-H) catalyzed by a CYP enzyme. Electrons (e ) are donated either 
from NADPH or from cytochrome b . Modified from 
-
5 [1]. 
 
 
 
1.3 CYP GENE SUPERFAMILY 
There are approximately 55 different CYP genes in the human genome, and these are further 
divided into families and subfamilies based on their sequence homology [5]. There have been 
identified 16 different CYP gene families and 29 subfamilies in humans up to date. Members 
of one gene family have more than 40% amino acid identity. Members of one subfamily have 
more than 55% amino acid identity [6]. 
 
Recommended nomenclature for CYP genes is italicized root symbol for human  CYP (CYP), 
representing “cytochrome P450”, followed by an Arabic number denoting the family (CYP3), 
a letter designating the subfamily (CYP3A), and an Arabic number representing the individual 
gene (CYP3A5) [7]. Proteins belonging to CYP families 1, 2 and 3 are largely involved in the 
biotransformations of xenobiotics, and they account for most of the metabolism of 
pharmaceuticals. Remaining CYP families are responsible for metabolism of endogenous 
substances, such as steroids and fatty acids [8]. 
 
CYP-Fe2+-O2--H 
CYP-Fe3+-O-D-H 
CYP-Fe3+
CYP-Fe3+-D-H 
CYP-Fe2+-D-H 
CYP-Fe2+-O2-DH 
D-H
e- 
O2
e- 
2H+ 
D-OH 
H2O 
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1.4 CYP3A SUBFAMILY 
The subfamily of CYP3A is of great importance, mainly because of its high amounts found in 
organs involved in drug disposition, such as liver, gastrointestinal tract and kidney; as well as 
because of its extremely broad substrate specificity. Liver is the organ where CYP3A 
isozymes make the largest proportion of the total CYP pool [9], and where they contribute to 
the metabolism of approximately 40 - 60% of all known oxidatively metabolized drugs [10]. 
Four members of the CYP3A subfamily have been described in humans: CYP3A4, CYP3A5, 
CYP3A7  and CYP3A43 [11]. CYP3A4 is the most abundant CYP 450 expressed in liver and 
intestine, and it contributes to metabolism of approximately 50% of all used drugs in humans 
[12].  
 
CYP3A7 is the major isoform of CYP enzymes found in foetal liver, where it accounts for 
between 30% and 50% of total CYP [13].  It is now established that this isoform is also found 
in adult liver, with recent studies suggesting that 20% of  adult livers express CYP3A7 [14, 
15]. In these 20%, this enzyme appears to be responsible for metabolism of approximately 
80% of retinoic acid [15, 16]. This means that hepatic expression of CYP3A7 in adults can be 
of potential interest in physiological pathways regulated by retinoic acid, as well as the 
outcomes of retinoic therapy. Additionally, CYP3A7 seems to metabolize estrone and 
dehydroepiandrosterone more efficiently than both CYP3A4 and CYP3A5, and it has also 
been showed expressed in several different steroid-responsive tissues [11]. This could be 
related to normal physiological processes, but also to increased susceptibility to cancer. 
 
CYP3A43 has recently been identified as a member of CYP3A subfamily in humans (2000) 
[17, 18]. This enzyme appears to have role in some physiological processes rather than in 
drug metabolism, but there is need for more research to understand the function of CYP3A43. 
 
1.4.1 Factors affecting CYP catalyzed biotransformations 
It is well known that the outcome of a given drug therapy can vary significantly between 
individuals. Since CYP enzymes are such major contributors to the metabolism of majority of 
drugs used in humans, it is clear that there are differences in their activity among individuals 
in a population. Exposure to some drugs and environmental pollutants can increase synthesis 
of de novo CYP enzymes, leading to increased rate of drugs’ biotransformation and lower 
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bioavailability. More often, CYP enzymes are inhibited during concomitant use of two or 
more drugs, competing for the same active site. 
 
1.5 CYP 3A5 ABUNDANCE 
CYP3A5 is the most studied of the so called minor CYP3A isoforms (other isoforms than 
CYP3A4) in humans, and it is often considered the second most important CYP3A protein in 
the liver. CYP3A5 is polymorphically expressed at approximately 20% of adult human livers 
[19-21], but it is also present extrahepatically; in gastrointestinal tract and the kidney [22]. 
Major characteristic of CYP3A5, as well as of other CYP enzymes, is the large range of the 
interindividual variation in the expression of enzymes [2]. Furthermore, there are interracial 
variations in the level of CYP3A5 expression, 10 to 30% of whites and approximately 50% of 
African Americans express hepatic CYP3A5 at readily detectable levels [23, 24].  In addition, 
it seems that the level of CYP3A5 in those expressing it, can approach that of CYP3A4 [24], 
but this is still questioned, as other investigators suggest lower levels in their experiments 
[25]. 
 
According to previously published research, CYP3A4 does not have defect alleles leading to 
absence of expression, and its interindividual variations in content are primarily caused by 
environmental factors [26]. The importance of the genetic polymorphism of CYP3A5 is 
widely discussed, and it is proposed that CYP3A5, for people expressing it, could be the most 
important genetic contributor to interindividual and interracial differences in CYP3A 
dependent metabolism. 
 
Several alleles of CYP3A5 exist, but only people with at least one CYP3A5*1 allele express 
high amounts of CYP3A5 enzyme [5]. Absence of CYP3A5 expression has been related to 
several different polymorphisms. It is now established that the most common cause of this 
absence is a single nucleotide polymorphism (SNP) in intron 3 of CYP3A5*3 allele (A6986G) 
[23]. This polymorphism leads to alternative splicing and protein truncation. Alleles with A at 
position 6986 encode a normally spliced CYP3A5 (CYP3A5*1 allele), but when G is present 
at this position (CYP3A5*3 allele), the insertion of material from intron 3 will lead to 
premature termination of translation. It is interesting to note that, for most CYPs, the first 
gene allele sequenced is usually the most common one, and is designated *1. This allele is 
also called “reference” or “wild type” sequence. In the case of CYP3A5, the reference 
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sequence CYP3A5*1, came from a liver sample expressing CYP3A5, meaning that it was a 
less common variant. 
 
1.5.1 Substrate specificity of CYP3A5 
CYP enzymes in general, have very low substrate specificity, opening for the possibility of 
two or more individual enzymes catalyzing the same reaction. CYP3A5 is structurally related 
to CYP3A4, and they also show overlapping substrate specificity [27]. CYP3A5 has a large 
hydrophobic active site with the heme part easily available for binding of substrates. This 
allows a wide variety of substrates to bind to the enzyme, possibly also at the same time 
(section 1.8) [27]. Although CYP3A5 metabolizes almost all substrates of CYP3A4, several 
studies have shown different regioselectivity and lower metabolic activity compared to 
CYP3A4. Up to date, there is discordance in results for the CYP3A5 metabolism of several 
known CYP3A4 substrates. For example, Wrighton et al. [19] have reported lower metabolic 
capacity of CYP3A5 compared to CYP3A4 towards testosterone, nifedipine and 
erythromycin. In contrast, Gillam et al. [28] suggest equal or even higher metabolic capacity 
than CYP3A4 towards the same substrates. Questions are also asked regarding CYP3A5 
metabolism of midazolam, which is a preferred probe substrate for CYP3A metabolism 
(section 1.7.3). William et al. [29, 30] report equal capacity of midazolam 1′-hydroxylation 
for CYP3A5 as for CYP3A4, while Patki et al. [31] conclude that CYP3A5 has significantly 
lower metabolic capacity towards midazolam than CYP3A4. Possible explanation of such 
differences in results could be different enzyme sources, conditions of incubation and 
availability of cofactors. 
 
1.6 MODELS FOR IN VITRO STUDIES OF CYP3A ACTIVITY 
In vitro studies are a useful tool in predicting drug metabolism in vivo. Advantage of using in 
vitro approaches in studying drug metabolisms is that the conditions can be more closely 
controlled and modified than in vivo. On the other hand, the chosen conditions may not reflect 
those in vivo, and it can be difficult to make conclusions from the in vitro results, especially 
quantitative.  
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There are two main strategies for in vitro investigation of a certain drug’s metabolism by CYP 
enzymes: 
• Incubation with intact cells (i.e. primary cell cultures, encapsulated hepatocytes or 
tissue slices) 
• Incubation with subcellular fractions (i.e. microsomes) [32] 
 
Cultured hepatocytes are usually obtained from liver transplant programmes and surgical 
waste [33]. Major limitation is that the cells used have to be fully differentiated, and sufficient 
growth in vitro can be difficult to obtain. Since fresh liver samples are not always available, 
cultured primary hepatocytes have limited use. However, it has been achieved to preserve 
adult hepatocytes by entrapping them in a polysaccharide matrix (“cryopreservation”), 
followed by freezing, and these cells are commercially available, used mostly for short-term 
experiments because of their reduced viability after thawing [34]. 
 
Over the past decades, CYP enzymes have been cloned and expressed in various cell lines. 
Transfected human lever epithelial cells (THLE cells) are an example of human cell lines 
used for this purpose. THLE cells are non-tumorigenic, immortalized liver epithelial cells, 
established by Gomez-Lechon [35]. They are obtained from cultured human liver epithelial 
cells immortalized by infection with the simian virus 40 large T antigen (SV40 T antigen) 
[36]. While they express some of the enzymes involved in phase II reactions (section 1.1), 
phase I enzymes, including CYP enzymes, have been detected at very low levels, or not 
detected at all, and that is why these cells are referred to as “neo-cells”. This makes THLE 
cells suitable for re-expression of individual CYP enzymes by transfection with their 
respective cDNA [37] .  
 
Liver slices are another example of intact cells used in metabolism studies. They are simple in 
use, but the cells have relatively low survival within the sliced tissue, even though it has been 
reported that they can survive for up to 24 hours [38]. 
 
1.6.1 Microsomal preparations 
Microsomes are subcellular fractions prepared from endoplasmatic reticulum, and they are 
widely used in metabolism studies. HLM (human liver microsomes) are microsomes isolated 
from human lever cells. They can be easily prepared from liver tissue by homogenization and 
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centrifugation, using well-established methods, and can be stored at -80ºC for several years, 
with little or no loss of CYP enzyme activities [39, 40]. 
 
With the development of genetic engineering, the use of recombinant systems as a source of 
microsomes has increased significantly [32]. Previously mentioned THLE cells can, besides 
from being used as intact cells in metabolism studies, also serve as a source of microsomes 
after transfection with cDNA coding for the CYP gene of interest. Their nearly unlimited life-
span is a great advantage, and since they are transfected with individual CYP genes, they are 
especially suitable for studying metabolism by that particular CYP enzyme, originating from a 
human liver cell. Human cDNA coding for individual CYP genes have also been isolated, 
reconstituted in vectors and transfected into other expression systems than human cells, such 
as insects, yeast and bacteria, along with a strong promoter, to achieve high levels of 
expression of the enzymes [32, 41].These techniques are a useful tool for obtaining large 
amounts of enzymes of interest.  
 
A clear advantage of intact cells, both primary hepatic cell cultures, transfected THLE cells 
and liver slices; is that the environment is more similar to the physiological one: plasma 
membrane, cofactors and genes expressed are all maintained, at least for a certain amount of 
time. These factors are of great value when results from in vitro studies are extrapolated to in 
vivo. Limitation of intact cells is that the metabolism observed reflects not only catalytic 
activity of the enzymes involved, but also other processes such as transport into the cell. 
 
Microsomes from recombinant systems need to be reconstituted with phospholipids and 
various cofactors, such as NADPH-P450 reductase, and, in some cases, cytochrome b5. 
Alternatively, some of these cofactors can be coexpressed in the used expression system, 
avoiding these problems. Selecting optimal incubation conditions is also of great importance, 
as reported by Hermann et al. [42], even though environment in vivo can never be duplicated 
in vitro. Finally, microsomes from recombinant systems and CYP transfected THLE cells, in 
contrast to HLM, do not provide quantitative information about the participation of a given 
isoenzyme in the overall metabolism of the drug.  
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1.7 MIDAZOLAM AS  AN IN VITRO PROBE 
 
1.7.1 General characteristics of midazolam 
Midazolam (MDZ) is a benzodiazepine with ultra-short duration of action (<6 hours, with 
great individual variations), mainly used as a hypnotic and an intravenous anaesthetic [43]. It 
binds selectively to the regulatory site of γ-aminobutyric acid A (GABAA) receptors in the 
brain, which mediate fast inhibitory synaptic transmission through the central nervous system 
(CNS). This type of binding, distinct from the GABA binding site, increases the affinity of 
GABA for the receptors [44]. 
 
1.7.2 Metabolism of midazolam 
Midazolam is a basic and lipophilic compound with a molecular weight of 325.8 g/mol. It is 
94-97% protein-bound and extensively hydroxylated in the liver and the intestine,  mainly to 
1′-hydroxy-midazolam (1′-OH-MDZ), which is an active metabolite with a half-life of 2 
hours, and to an inactive secondary metabolite 4-hydroxy-midazolam (4-OH-MDZ) (Figure 3) 
[45].  The biotransformation of MDZ is catalyzed by at least three different CYP3A enzymes: 
CYP3A4, CYP3A5 and CYP3A7 [5, 46]. Up to 80% of midazolam is recovered in the urine 
as 1′-OH-MDZ-glucuronide [3]. 
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Figure 3: Metabolic pathway of midazolam with the formation of the major, active metabolite 1′-OH-
midazolam, and the secondary, inactive 4-OH-midazolam. 
 
1.7.3 Midazolam as a probe substance 
Since CYP3A enzymes are responsible for metabolism of majority of currently used drugs 
(section 1.3), it is very important to use a standardized CYP3A probe substrate, especially 
when findings from different studies and drugs are compared. MDZ is the preferred in vivo 
and in vitro CYP3A probe recommended by the US Food and Drug Administration (FDA) 
and the Pharmaceutical Research and Manufacturers of America [47]. Some of several 
characteristics that make MDZ preferred in vitro CYP3A probe are: 
• It is exclusively metabolized by CYP3A4/CYP3A5 to a primary metabolite 1′-
hydroxymidazolam [46]. 
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• It is highly sensitive to changes in the activity of the CYP3A4/CYP3A5 enzymes [48, 
49]. 
• It is not a substrate for P-glycoprotein [50]. 
• It is commercially available. 
• It is metabolized to an comparable extent by both intestinal and hepatic CYP3A, 
making it possible to study effects of CYP3A in both the gut and the liver [51, 52]. 
 
1.8 ENZYME KINETICS 
Substrate affinity and catalytic capacity are kinetic parameters used to quantitatively describe 
certain enzyme’s properties as a catalyst in metabolic reactions. The process of enzymatically 
catalyzed reaction is often described using following equation: 
 
PEESSE 31
k
2
+⎯→⎯+ ⎯→⎯⎯⎯← kk                                               (Equation 1)                    
 
 
where E is the enzyme, S is the substrate, ES is the formed enzyme - substrate complex, P is 
the formed metabolite, k1 and k2 are the association and dissociation constants, respectively, 
and k3 is the catalytic rate constant. According to equation 1, formation of ES =E x S x k1, 
while elimination of ES = (ES x k2) + (ES x k3). Steady - state is achieved when amount of 
formed ES equals amount of ES eliminated.  
 
Under the assumption of steady state conditions, Lenor Michaelis and Maud Menten 
suggested an equation that relates the velocity of a reaction (v) to the substrate concentration 
(S), Michaelis-Menten equation: 
 
 
SK
SV
m
max
+
×=v                                                            (Equation 2)   
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Vmax is the maximum velocity of the reaction, and it expresses the content of enzymes. The 
higher the content of enzymes (higher Vmax), the higher is the catalytic activity. Km is called 
the Michaelis-Menten constant, describing the substrate’s affinity towards the enzyme, and it 
is constant for a given substrate. A typical Michaelis-Menten plot is showed in Figure 4. 
Initially, reaction rate increases hyperbolically until it reaches maximum (Vmax). Substrate 
concentration [S] equals Km when reaction rate (v) is 50% of the maximum velocity (Vmax), 
and it will not be affected by the amount of enzymes available.   
 
[S]
v
 
Figure 4: Hyperbolic curve representing reaction following classical Michaelis-Menten model. 
 
 
Pharmacokinetic properties of the majority of CYP metabolized drugs can be predicted with 
the classical Michaelis-Menten kinetic analysis. However, some CYP catalyzed drug 
reactions show kinetic behaviour that is referred to as atypical, where a plot of substrate 
concentration versus reaction velocity does not follow a Michaelis-Menten hyperbola, and 
this unusual type of enzyme kinetics has often been associated with CYP3A metabolism. One 
important assumption of the Michaelis-Menten model is that substrate - enzyme interactions 
occur at only one site per enzyme, and that each site functions independently from others. 
There is evidence suggesting that this is not the case for some CYP3A enzymes, including the 
clinically most important CYP3A enzyme, CYP3A4. [53]. Several models based on the 
existence of several binding sites within the enzyme have been proposed to explain the 
unusual enzyme kinetics in some CYP3A substrates:  
• Simultaneous binding of two substrate molecules within the active site of the enzyme 
[54] 
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• Binding of multiple substrate molecules to the enzyme due to existence of at least 
three subpockets in the active site, including one allosteric site too distal from the 
heme for metabolism to occur [55] 
• Existence of multiple conformations of the enzyme [56] 
• “Nested model” where the relative proportions of the multiple conformers are 
determined by allosteric effectors [29] 
 
Atypical enzyme kinetics include activation, substrate inhibition and autoactivation [54]. An 
important characteristic of CYP3A enzymes is that their catalytic activity for a certain 
substrate can be activated by the addition of another xenobiotic to the incubation mixture in 
vitro, and this phenomenon is called positive cooperativity/allosterism [53]. Moreover, 
increasing concentrations of some CYP3A substrates, such as midazolam, have been found to 
stimulate their own metabolism, a phenomenon referred to as autoactivation. Substrate 
inhibition on the other hand, occurs when an increase in substrate concentration over a certain 
value results in a decrease in the metabolism rate, and this is often called negative 
cooperativity/allosterism [45].  There are two main types of curves for the metabolism of 
drugs whose kinetics show deviation from standard hyperbolic Michaelis-Menten plots: 
1. Sigmoid (Figure 5A), believed to result from activation, and 
2. Convex (Figure 5B), believed to result from substrate inhibition. 
 
A
[S]
v
B
[S]
v
 
 
Figure 5: Example of plots showing atypical kinetics. (A) Sigmoidal curve caused by autoactivation. (B) 
Convex curve resulting from substrate inhibition. 
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Substrate activation resulting in a sigmoid curve (Figure 5A), with an initial delay, is often 
described by Hill’s equation: 
 
nn
50
n
max
SS
SV
+
×=v                                                                                 (Equation 3) 
 
where S50n is analogous to the Km parameter in Michaelis-Menten equation (Equation 2), and 
n is Hill’s coefficient. Metabolic reactions showing convex curves (Figure 5B) can be 
quantitatively described using the equation for uncompetitive inhibition: 
 
))(S/K/S)(K(1
V
sim
max
++=v                                                          (Equation 4) 
 
where Ksi is a constant describing the substrate inhibition reaction. 
 
When kinetic results of in vitro experiments are extrapolated to in vivo metabolic activity, the 
concept of intrinsic clearance (CLint) is used. The CLint is defined as the velocity (v) of the 
enzymatic reaction divided by the substrate concentration (S) and can be described by 
following equation: 
SK
VCL
m
max
int +=                                                                                   (Equation 5) 
 
The in vitro CLint value is then scaled-up to reflect CLint in vivo, and inserted into a model of 
hepatic expression [57]. 
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1.9 AIM 
CYP3A5 is the most clinically important CYP3A enzyme after CYP3A4. In contrast to 
CYP3A4, the expression of CYP3A5 in individuals is genetically determined, where only 
people with at least one CYP3A5*1 allele express functional CYP3A5 proteins, and the 
proportion of individuals polymorphically expressing CYP3A5 is approximately 20%. 
CYP3A5 has showed overlapping substrate specificity with CYP3A4. Genetic polymorphism 
in the expression of CYP3A5 could be the most important contributor to the interindividual 
variations in the CYP3A catalyzed metabolism, but the extent of CYP3A5 metabolism of 
drugs that are known to be metabolized by CYP3A4 is under investigation.  
 
In vitro studies using recombinant systems are extensively applied in order to determine 
enzyme kinetic parameters such as Vmax, Km and CLint, which in turn, are extrapolated to 
predict pharmacokinetic properties of drugs in vivo. In the literature, different enzyme kinetics 
have been observed using the same substrate for CYP3A5. Additionally, various observations 
have been related to different laboratories performing the experiments. Therefore, the aim of 
the present thesis was to investigate and compare metabolism of midazolam, which is a probe 
substrate for the CYP3A activity, in different recombinant in vitro systems expressing human 
CYP3A5. In addition, human liver epithelial cells were to be transfected with human DNA 
coding for CYP3A5 enzymes, in order to obtain a stable source of CYP3A5 proteins 
originating from human cells. 
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2 MATERIALS AND METHODS 
 
2.1 MATERIALS 
1′-hydroxy-midazolam Sigma-Aldrich, St. Louis, Missouri, USA 
4-hydroxy-midazolam Sigma-Aldrich, St. Louis, Missouri, USA 
Acetonitrile, HPLC grade Merck, Darmstadt, Germany 
Acryl-amide/Bis solution Bio-Rad Laboratories Inc, California, USA 
Agarose, electrophoresis grade Life Technologies, Paisley, UK 
Agilent Total RNA Isolation Mini Kit 
Agilent Technologies, Palo Alto, California, 
USA 
Alcohol, absolute Prima Arcus Kjemi AS, Oslo, Norway 
Ampli Taq Gold® 
Applied Biosystems, Roche Molecular 
Systems Inc, Branchburg , New Jersey, USA 
Anti - CYP3A5 (gift) 
Clinical Pharmacology, Imperial College 
School of Medicine, Hammersmith Hospital, 
UK 
APS Bio-Rad Laboratories Inc, California, USA 
Blasticidin S HCl Invitrogen, Carlsbad, California, USA 
BPE (6mg/mL ), Biofluids no.210 Biofluids, Rockville, California, USA 
Brom-phenol-blue Bio-Rad Laboratories, Inc, California, USA 
BSA (3%), Sigma no. A-9418 Sigma-Aldrich, St.Louis, Missouri, USA 
Deionised water Easypure UV, Barnstead, Iowa, USA 
Diazepam (gift) Diakonhjemmet Hospital, Oslo, Norway 
Distilled water 
Aquatron A4S, Bibby Science Products SA, 
France 
ECL Western Blotting Detection reagent 
Amersham pharmacia biotech, Cambridge, 
England 
EGF (5µg/mL), Biofluids no.372 Biofluids, Rockville, California, USA 
Ethanol Merck, Darmstadt, Germany 
Fat free dry milk (gift) Normilk AS, Oslo, Norway 
FBS Gibco, Paisley, UK 
Fibronectin PAA Laboratories GmbH, Pasching, Austria 
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Formic acid, analytical grade Merck, Darmstadt, Germany 
GeneAmp®
Applied Biosystems, Roche Molecular 
Systems Inc, Branchburg, New Jersey, USA 
Gentamycin (10 mg/ML) 
Life Technologies, A/S E.Pedersen & Sønn, 
Oslo, Norway 
Glycerol Sigma-Aldrich, St. Louis, Missouri, USA 
Hanks’ Balanced Salt Solution PAA Laboratories Gmbh, Pasching, Austria 
HEPES Sigma-Aldrich, St. Louis, Missouri, USA 
Human fibronectin Sigma-Aldrich, St. Louis, Missouri, USA 
Humane lever microsomes Invitrogen, Carlsbad, California, USA 
Hybond-ECL nitrocellulose membrane 
Amersham pharmacia biotech, Cambridge, 
England 
Hydrocortisone (10 mM), Biofluids no. 346 Biofluids, Rockville, California, USA 
Insuline (0.35 mM), Biofluids no. 350 Biofluids, Rockville, California, USA 
Isobutanol Merck, Darmstadt, Germany 
KCl Merck, Darmstadt, Germany 
Kodak AL-4 x-ray fixer Sigma-Aldrich, St. Louis, Missouri, USA 
Kodak BioMax MS Film Sigma-Aldrich, St.Louis, Missouri, USA 
Kodak LX-24 x-ray developer Sigma-Aldrich, St. Louis, Missouri, USA 
L-glutamine (200 mM) 
Life Technologies, A/S E. Pedersen & Sønn, 
Oslo, Norway 
Lipofectin® Reagent Invitrogen, Carlsbad, California, USA 
Methanol, HPLC grade Merck, Darmstadt, Germany 
MgSO4 Merck, Darmstadt, Germany 
MgSO4*H2O, analytical grade Merck, Darmstadt, Germany 
Midazolam (gift) 
F. Hoffmann-La Roche Ltd, Basel, 
Switzerland 
NADPH Sigma-Aldrich, St. Louis, Missouri, USA 
NaOH Merck, Darmstadt, Germany 
Nitrogen gas AGA Progas A/S, Oslo, Norway 
P/E (0.1 mM), Biofluids no. 353 Biofluids, Rockville, California, USA 
Pef6/V5-His-Topo®/lacZ vector Invitrogen, Carlsbad, California, USA 
PFMR-4 medium, Biofluids no. 145 Biofluids, Rockville, California, USA 
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Ponceau S-solution Sigma-Aldrich, St. Louis, Missouri, USA 
Precision Plus protein standard (Dual 
Colour) 
Bio-Rad Laboratories Inc, California, USA 
Primers Invitrogen, Carlsbad, California, USA 
RA (3.3 µM), Biofluids no. 348 Biofluids, Rockville, California, USA 
SDS Bio-Rad Laboratories Inc, California, USA 
SDS-PAGE standard (Low Range) Bio-Rad Laboratories Inc, California, USA 
Sodium butyrate Sigma-Aldrich, St. Louis, Missouri, USA 
Sucrose Merck, Darmstadt, Germany 
Supersomes® expressing CYP3A5 
Larodan Fine Chemicals AB, Malmö, 
Sweden 
TaqMan® Reverse Transcription Reagents 
Applied Biosystems, Roche Molecular 
Systems Inc, Branchbrug, New Jersey, USA 
Transferrin (5 mg/mL), Biofluids no. 352 Biofluids, Rockville, California, USA 
Triiodthyronine (1 mM), Biofluids no. 354 Biofluids, Rockville, California, USA 
Trypsin-EDTA (1x), 0.05 % Trypsin, 0.53  
Mm EDTA*4 Na 
Gibco, Paisley, UK 
Tryptan Blue Sigma-Aldrich, St. Louis, Missouri, USA 
Tween 20 Bio-Rad Laboratories, Inc, California, USA 
THLE cells 
Nestlé Research Centre, Lausanne, 
Switzerland 
β – Gal Staining Kit Invitrogen, Carlsbad, California, USA 
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2.2 EQUIPMENT 
75 cm2 Flasks, Corning® CellBIND® Surface 
Corning Incorporated, Corning, New York, 
USA 
Citenco shaking water bath Citenco LTD, Horeham Wood, England 
Bürker counting chamber Assistant, Sontheim, Germany 
Class VP Chromatography, Datasystem 
Version 4.3 LC-10AD VP software 
Shimadzu, Japan 
DGU – 14A degasser Shimadzu, Japan 
Digital camera: Olympus Camedia C-7070 Olympus Norway A/S, Oslo, Norway 
FCV-10ALVP mixing chamber Shimadzu, Japan 
GeneAmp PCR System 9700 
PE Applied Biosystems, Foster City, 
California, USA 
GeneQuant pro RNA/DNA Calculator 
Amersham pharmacia biotech, Cambridge, 
England 
Incubator: Nuaire US Autoflow NuAire, Plymouth, Maryland, USA 
Inertsil C8, 50*3 mm 5 µM particle size 
colon 
Varian, USA 
Kubota 2010 centrifuge Medinor, Oslo, Norway 
LAF bench: Holten LaminAir Medinor, Oslo, Norway 
Multiple Well plate, 6 well 
Corning® CellBIND® Surface 
Corning Incorporated, Corning, New York, 
USA 
Nitrogentank: Locator 8 plus 
Barnstead International, Dubuque, Iowa, 
USA 
Phase contrast microscope: Olympus CKX41 Olympus Norway A/S, Oslo, Norway 
SCL-10AVP system controller Shimadzu, Japan 
Sil-10 AD VP auto sampler / injector Shimadzu, Japan 
Universal 32R centrifuge Hettich Zentrifugen, Tuttlingen, Germany 
Water bath: thermostat HWT 100 Heto Holten, Oslo, Norway 
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2.3 CULTURING OF THLE CELLS 
All the work with the THLE cells (Nestlé Research Centre, Lausanne, Switzerland) (section 
1.6) was done in a LAF bench using aseptic working procedures. The cells were incubated at 
37˚C in a humidified 3.5% CO2 atmosphere. Culturing of the cells was performed in pre-
coated 75 cm2 flasks, six-well plates and 60 mm plates in a serum free medium (PFMR-4) 
(section 7.1.1). The growth medium (PMFR-4) was changed every other day. The cells were 
grown in 12 mL, 2 mL and 4 mL medium per flask, well and plate, respectively. 
 
 
                
4 x magnification     10 x magnification 
 
               
20 x magnification     20 x magnification 
 
Figure 6: Pictures of THLE cells cultured in 75 cm2 flasks. The grades of magnifications are marked under each 
picture. 
 27
                                                                                                  MATERIALS AND METHODS   
 
2.3.1 Thawing of cells 
An ampoule of 1 mL THLE cells, clone T5 cl5, was rapidly thawed at 37˚C. The cells were 
resuspended in a coated 75 cm2 culture flask containing 11 mL prewarmed (37 ˚C) growth 
medium (PMFR-4). The cells were incubated at 37˚C in a humidified 3.5% CO2 atmosphere. 
Growth medium was changed every other day until the flasks were approximately 90% 
confluent. 
 
2.3.2 Splitting of cells 
The cells were splitted at 90% confluence, which was usually every sixth to seventh day. Each 
flask then contained approximately 12x106 cells. At that point, the old growth medium was 
removed and the cells were washed with 5 mL HBSS (Hanks’ Balanced Salt Solution). 
Subsequently, the cells were detached from the flask by adding 2 mL trypsin-EDTA 
(ethylenediaminetetraacetic acid) diluted with HBSS (1:1, v/v). Trypsin is a proteolytic 
enzyme, used in combination with chelator EDTA to detach the cells from the surface of the 
culturing flasks. After 5 minutes incubation at 37˚C, the cells were brought into suspension by 
tapping the sidewalls of the flask. In order to deactivate trypsin, 5 mL HBSS with 2.5% foetal 
bovine serum (FBS) was added to the cells. The cell suspension was transferred to a tube and 
centrifuged for 5 minutes at 200 g (Kubota 2010 centrifuge, Medinor, Oslo, Norway). 
Afterwards, the supernatant was removed and the cell pellet was resuspended in growth 
medium. The cells were further seeded into flasks, 60 mm plates and six-well plates, at 
densities of 1.5x106, 3.5x105 and 2.5x105 cells per flask, plate and well, respectively.  
 
2.3.3 Freezing of cells 
The cells were splitted following procedure described in section 2.3.2. Cell pellets from two 
75 cm2 flasks were resuspended in 1 mL growth medium and added 1 mL FBS and 20% (v/v) 
dimethyl sulfoxide (DMSO), which had been previously diluted with the growth medium. The 
suspension was mixed gently and transferred to a Nunc vial with a cell density of 2-5x106 
cells per mL. The cells were frozen at -70ºC over the night and then transferred to nitrogen 
tank (-196°C).  
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2.4 TRANSFECTION OF THLE CELLS 
Molecular cloning is a process where a DNA fragment of interest is recombined with a vector 
and introduced in a suitable host, which then becomes genetically modified. DNA plasmids 
are commonly used cloning vectors, obtained in high amounts by transformation of bacteria.  
Since the term transformation in mammalian cells is used to describe conversion of cells to 
malignant state, the introduction of foreign DNA in mammalian cells is called transfection. In 
stable transfection, the plasmid DNA integrates into the genome, resulting in formation of a 
cell line carrying and expressing the transgene. Transfection in the present thesis was 
performed using Lipofectin® Reagent (Invitrogen), which is a cationic lipid compound with a 
basic structure consisting of a positively charged head group and a hydrocarbon chain. The 
charged head groups govern the interaction between the lipid and the phosphate backbone of 
the DNA, leading to the formation of the DNA-lipid cationic complexes. The positive surface 
charge of the hydrophilic head of the complexes mediates their interaction with the cell 
membranes, leading to their uptake into the cells through endocytosis. Thus, cationic lipid 
reagents, such as Lipofectin® Reagent, are thought to facilitate transfection during the early 
steps of the process by mediating DNA condensation and DNA/cellular interactions.    
 
2.4.1 The plasmid 
The vector used for transfection of THLE-cells, pEF6/V5 –His-Topo® vector (Invitrogen), 
contains ampicillin resistance gene (β-lactamase), which is used for selection of transformants 
in Escherichia coli (E.coli). The vector also contains blasticidin resistance gene, Blasticidin S 
deaminase (bsd), which is used for selection of stable transfectants in mammalian cells. Gene 
coding for CYP3A5 is also inserted in this vector. 
 
2.4.2 Stable transfection of THLE cells  
The THLE cells were seeded onto 60 mm plates 2 days before transfection in the PFMR-4 
medium without antibiotics. Cells were transfected with pEF6/V5-His-Topo® vector 
(Invitrogen) with CYP3A5 inserted. For each transfection sample, plasmid DNA was diluted 
in 100 µL PFMR-4 medium without any additives. Lipofectin® Reagent was diluted with 100 
µL PFMR-4 medium without any additives, mixed and incubated for 45 minutes at room 
temperature. The diluted DNA was combined with the diluted Lipofectin® Reagent, mixed 
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gently and incubated for 15 minutes at room temperature. The growth medium was removed 
from the cells. Afterwards, 1.8 mL of PFMR-4 culturing medium without antibiotics was 
added to the complexes. The suspensions were mixed gently and added to the cells. The cells 
were incubated for 24 hours at 37˚C in a humidified 3.5% CO2 atmosphere. Experimental 
conditions used under transfection are described in Table 1. After the transfection incubation 
time, the medium was removed and the cells were washed with 4 mL HBSS. Thereafter, 4 mL 
complete PFMR-4 medium was added to each plate. The cells were incubated at 37˚C in a 
humidified 3.5% atmosphere. After incubation for 2 days, the cells were splitted as described 
in section 2.3.2, but this time using 2 mL HBSS, 1 mL Trypsin-EDTA diluted with HBSS 
(1:1, v/v) and 2.5 mL HBSS with 2.5% FBS per plate. To kill untransfected cells, blasticidin 
was added to the growth medium to a final concentration of 2 µg/mL three days after the first 
splitting. The culture medium containing 2 µg/mL blasticidin was changed every other day. 
After culturing with blasticidin (2µg/mL) for ten days, the cells were splitted as described 
above and seeded onto new coated six-well plates and further into 75 cm2 flasks, as the cells 
were growing. The rest of the cell suspensions were used for total RNA isolation (section 
2.5.1).  
 
Table 1: Experimental conditions used under transfection of THLE cells with CYP3A5 
 
Cell density at seeding 3.5x105 cells per plate  
Day of transfection (day 0 set to the day when 
seeding of cells was performed) 
2 
Amount DNA (µg) 1, 2 
Lipofectin® Reagent (µL) to DNA (µg) ratio 5:1 
Incubation time of Lipofectin® and PFMR-4 
medium without additives 
45 minutes 
Incubation time of Lipofectin® Reagent-DNA 
complex before adding to cells 
15 minutes 
BSA present in the culturing medium at the 
time of transfection 
Yes 
Antibiotics present in the culturing medium at 
the time of transfection  
No 
BSA present at the time of DNA-Lipofectin® 
Reagent complex formation 
No 
Transfection incubation time 24 hours 
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2.5 STUDIES OF GENE EXPRESSION OF CYP3A5  
Gene expression of CYP3A5 in the transfected cells was performed using reverse 
transcriptase- (RT) PCR analysis. In order to be able to apply PCR analysis to the study of 
mRNA, the mRNA samples were first isolated from the transfected cells, and then reverse-
transcribed to complementary DNA (cDNA). Thereafter, amplification of the cDNA sequence 
was performed by use of the PCR technique. PCR is a method where DNA polymerase is 
used for exponential amplification of nucleic acids in vitro by repeated thermal cycling. The 
double-stranded DNA is first heat-denatured at high temperature, then annealed at a lower 
temperature to two oligonucleotide primers, and finally extended at intermediate temperature. 
The amount of CYP3A5 cDNA was compared to the amount of β-actin (housekeeping gene) 
cDNA in each sample. 
 
2.5.1 Total RNA isolation and quantification 
Isolation of total RNA was performed by use of Agilent Total RNA Isolation Mini Kit®. One 
day before cell lysis, the cells were stimulated with sodium butyrate, which was added to the 
growth medium to a final concentration of 5 µg/mL. Splitting of cells was performed as 
described in section 2.3.2, but this time the cell suspension was centrifuged at 200 g (Kubota 
2010 centrifuge, Medinor, Oslo, Norway) for 5 minutes and the supernatant was removed. 
Further, washing of the cell pellet was performed one time by adding 1 mL x HBSS. 
Subsequently, 300 µL of prepared (10 µL β-ME /mL) lysis solution was added to each tube. 
The cell-homogenate was transferred to mini prefiltration column and centrifuged through the 
column for 3 minutes at 16 000 g (Universal 32R centrifuge, Hettich Zentrifugen, Tuttlingen, 
Germany). Subsequently, an equal volume (300 µL) of 70% ethanol was added to the filtrate, 
mixed and incubated for 5 minutes. The ethanol/lysis mixture was added to the mini-isolation 
column and then centrifuged for 30 seconds at 16 000 g. The flow-through was discarded and 
the RNA loaded column replaced into the same collection tube. An amount of 500 µL of 
previously prepared wash solution (to which ethanol has been added) was added to the mini-
isolation column in the collection tube, then centrifuged for 30 seconds at 16 000 g. The flow-
through was discarded, and the mini-isolation column replaced in the collection tube. 
Washing process, followed by centrifuging was repeated one more time. Subsequently, the 
mini-isolation column was centrifuged for 2 minutes at 16 000 g. Elution of purified RNA 
was performed by adding 10 µL of nuclease-free water. After incubation for at least 1 minute, 
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the column was centrifuged for 1 minute at 16 000 g. To determine the RNA concentration, 2 
µL of the RNA solution was diluted with 68 µL nuclease-free water. Determination of RNA 
concentration was performed by measuring absorbance at 260 nm with GeneQuant Pro 
RNA/DNA Calculator (Amersham pharmacia biotech, Cambridge, England). The RNA purity 
was determined by using a ratio of the absorbance at 260 nm and 280 nm. Pure RNA solution 
should have a 260/280 ratio of 1.9-2.1. 
 
2.5.2 Reverse transcriptase (RT) 
RT was performed by use of TaqMan® Reverse Transcription Reagents. RT-reaction mix was 
prepared and it consisted of: 2.0 µL 10xTaqMan RT Buffer, 4.4 µL MgCl2 (25 µM), 4.0 µL 
dNTP mix (10 mM), 1.0 µL Random hexamers (50 µM), 0.4 µL Rnase inhibitor (20 U/µL) 
and 0.5 µL Multiscribe Reverse Transcriptase (50 U/µL), volumes given per sample. 
Subsequently, 12.3 µL of the mixture was pipetted to each PCR tube. Thereafter, a total 
volume of 7.7 µL DEPC-dH2O and mRNA sample (1 µg) was added to PCR tubes. RT was 
run by use of GeneAmp PCR System 9700 (PE Applied Biosystems, Foster City, California, 
USA). RT – conditions were set to 10 minutes at 25˚C (hexamer/template priming), 1 hour at 
37˚C (reverse transcription) and 5 minutes at 99˚C (reverse transcriptase inactivation). 
 
2.5.3 Polymerase chain reaction (PCR) 
PCR was performed by use of AmpliTaqGold® with GeneAmp® reagents. The reaction mix 
was prepared and it consisted of: 5.0 µL 10xPCR Buffer, 1.5 µL MgCl2 (50 µM), 1.0 µL 
dNTP mix (10 mM), 1.5 µL Primer R, 1.5 µL Primer F, 0.3 µL Taq DNA polymerase (5 
U/µL, AmpliTaq Gold), volumes given per sample. PCR reaction mix was aliqouted to the 
PCR tubes. Finally, 29.8 µL DEPC-dH2O and 10 µL cDNA sample (RT-product) was added 
to each tube. PCR was run by use of GeneAmp PCR System 9700 (PE Applied Biosystems, 
Foster City, California, USA). The amplification program was initially started at 94˚C for 3 
minutes, thereafter 35 cycles of the following three steps: 94˚C for 45 seconds, 55˚C for 30 
minutes, and finally 72˚C for 5 minutes. 
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Primers: 
CYP3A5:   Fragment length: 75 base pairs (bp) 
Forward CYP3A5:  5’-GGT GAT TCC AAC TTA TGC TCT TCA-3’ 
Reverse CYP3A5:  5’-AAC CTT TCA GGG CGG ACC TC-3’ 
 
β – actin (positive control):  Fragment length 62 bp 
Forward β – actin:   5`-ACCGAGCGCGGCTACA-3` 
Reverse β – actin:   5`- TCCTTAATGTCACGCACGATTT-3` 
 
2.5.4 Agarose gel electrophoresis 
DNA fragments obtained in RT-PCR were separated on a 2% agarose gel by electrophoresis. 
To prepare the gel, 2 g agarose was dissolved in 100 mL 1xTBE buffer by heating up to 
boiling point in a microwave oven. After the solution was cooled down a bit, 10 µL (5 
mg/mL) ethidium bromide was added and stirred well. The warm solution was poured into the 
electrophoresis chamber. The gel was allowed to set at room temperature and then covered 
with 1xTBE buffer. Subsequently, 15 µL of each PCR product was mixed with 3 µL loading 
dye buffer and applied to the wells. For determination of the sizes of the DNA fragments, 15 
µL of standard low molecular weight DNA ladder (0.1 µg/µL) was applied to one well. The 
gel was run at 100 V for approximately 1.5 hours. The DNA was visualized by use of UV-
light. 
 
2.6 STUDIES OF CYP3A5 PROTEIN EXPRESSION 
To investigate expression of CYP3A5 proteins in the THLE cells transfected with CYP3A5, 
electrophoresis was performed. Electrophoresis is a method whereby charged molecules in 
solution, e.g. proteins, migrate in response to an electrical field; the rate of migration being 
determined primarily by the strength of the field and the net charge, size, and shape of the 
molecules. Since an anionic detergent sodium dodecylsulfate (SDS) preparation was used, 
which denatures proteins by conferring a net negative charge proportional to their length, the 
migration rate was determined only by the molecular weight of the proteins. Migration of 
proteins was carried out in polyacrylamide gels, mounted between two buffer chambers 
containing separate electrodes. The buffer used was Laemmli system, which is a 
discontinuous buffer system. In a system like that, a non restrictive large pore gel, the 
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stacking gel, is layered on top of the separating gel. The advantage of Laemmli gel is greater 
resolution because the treated proteins are stacked in a stacking gel before entering the 
separating gel. The proteins in the samples were analyzed by transferring them to a 
membrane, where they were detected chemiluminescently after being bound to the specific 
antibodies. 
 
2.6.1 Preparation of the samples from the CYP3A5 transfected THLE cells for protein 
electrophoresis 
CYP3A5 transfected THLE cells were cultured in a 60 mm plate with 4 mL complete PFMR-4 
culturing medium. Before harvesting for the protein analysis, the cells were rinsed twice with 
HBSS. To detach them from the culturing plate, 300 µL of sample buffer (section 7.1.5) was 
added to the cells. The cells suspended in sample buffer were then transferred to a heat-
resistant vial and cooked on a water bath for 5 minutes. Beta - mercaptoethanol (10%, v/v) 
and  brom - phenol - blue (5%, v/v) was added to the vial and cooked on a water bath for 
additional 5 minutes, before it was frozen at -20ºC.   
 
2.6.2 Electrophoresis 
Two pieces of 10% separating gel solutions were prepared as described in section 7.1.4. 
Ammonium persulfate and TEMED were left out and added last, simultaneously. The solution 
was gently swirled and pipetted to the glass sandwich to a level about 1.0 cm from the top. 
The glass sandwich was made of two glass plates and two metal plates making two cassettes, 
separated by two spacer strips at the edges, and clamped together to make a tight seal.  To 
prevent formation of meniscus on the top of the gel, which could cause distortion of the 
banding pattern, 200 µL of isobutanol was applied to the gel-containing cassettes before 
polymerization. The gels were allowed to polymerize for 45 minutes, when isobutanol was 
poured from the surface, and gels were rinsed with distilled water. Stacking gel (4%) was 
prepared according to section 7.1.4 and added to the sandwich. Combs were inserted into each 
gel. The gels were allowed to set for another 40 minutes. After that, the two gel-containing 
cassettes were rinsed with distilled water and placed in an electrophoresis chamber, which 
was then filled with Tank buffer until the cassettes were immersed in buffer. The combs were 
carefully removed from the gels. Volumes of 5 µL of protein standard and 15 µL of samples 
were applied to the wells and separated by electrophoresis at 200 V for 1 hour.  
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2.6.3 Western-blot 
Proteins separated on gel by electrophoresis were transferred to nitrocellulose membranes by 
a technique called blotting. After the electrophoresis was run, the cassettes were disassembled 
and stacking gel was removed from the separating gels and discarded. Gels, blotter papers, 
nitrocellulose membranes and cellophane sheets were all soaked in blotting buffer (section 
7.1.4), and then arranged in a “transphor sandwich” (Figure 7). Gels were blotted at 100 mA 
for 1 hour, with electric field applied perpendicular to the gels, making the proteins move out 
to the membrane. To verify successful protein transfer after blotting, membranes were stained 
for 1 min with Ponceau S-solution and rinsed with distilled water. Membranes were placed in 
tris - tween - buffered - saline - solution (T-TBS solution) (section 7.1.4) for 10 minutes. T-
TBS was discarded, 15 mL of blotto - solution (section 7.1.4) was added to each membrane 
and they were allowed to set for 60 minutes before addition of 15 mL of 1:10 000 primary 
CYP3A5 antibodies to each membrane, allowing them to incubate in a cold room over the 
night. Membranes were then washed at room temperature for 3x10 minutes in blotto prior to 
addition of the secondary antibodies, goat – anti – mouse diluted 1:3000 in blotto, followed by 
additional 1 hour of incubation at room temperature. Membranes were then washed 3x10 
minutes in blotto and 2x10 minutes in T-TBS. Equal amounts of chemiluminescense (ECL) - 
reagents (6 mL total volume) were mixed and added to the membranes, which were then 
packed in plastic folium with protein side facing down. The membranes were transferred to a 
film cassette and exposed to film for 5 minutes. The film was developed and fixated (section 
7.1.4). 
 
 Figure 7: Arrangement of the filter (blotter) paper, membranes, cellophane sheet, and gels for transphor. A 
transphor sandwich consists of one piece of filter paper, one membrane and one gel. 
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2.7 METABOLISM STUDIES 
Metabolism studies of midazolam were performed in different recombinant microsomal 
preparations: the microsomes from baculovirus infected insect cells specifically expressing 
CYP3A5 (Supersomes®), with or without coexpressed cytochrome b5, and the microsomes 
isolated from the CYP3A5 transfected THLE cells. 
 
2.7.1 Metabolism studies of midazolam in Supersomes® as a function of time   
The experiments of midazolam metabolism as a function of time (5-20 minutes) were 
conducted to establish reaction conditions that would ensure linearity of product formation 
with incubation times. Two substrate concentration were used, 3 µM and 50 µM midazolam. 
Incubations contained Supersomes® with or without coexpressed cytochrome b5. Incubation 
conditions used were established by Hermann et al. [42]. Midazolam solved in methanol was 
added to a vial, and the methanol was evaporated to dryness under nitrogen gas. A previously 
prepared incubation buffer, containing Tris-H2SO4 (pH 7.4), MgSO4 and NADPH was added 
to the vial with midazolam and mixed. Additional incubation buffer was added to each vial, so 
that the final volume was 170.5 µL / vial and the final concentration of the incubation buffer 
was 118 mM Tris-H2SO4 (pH 7.4), 0.5 mM MgSO4 and 1.6 mM NADPH. Vials containing 
midazolam and incubation buffer were preincubated in a 37˚C water bath for 5 minutes, while 
the Supersomes® with or without coexpressed cytochrome b5, diluted 1:64 in a buffer 
consisting of 10 mM HEPES, 2 mM EDTA and 0.25 M sucrose, were preincubated in a 37˚C 
water bath for 2 minutes. The metabolism was initialized by adding 50 µL of the microsomes 
solution to each vial with 30 seconds intervals. The mixtures were incubated in a 37˚C 
shaking (grade 7.5) water bath for 5, 10, 15 and 20 minutes, respectively, for both 
concentrations of midazolam. Incubations were terminated by adding 150 µL ice cold 
acetonitrile (ACN) with 0.044 µM internal standard diazepam (DIA) to each incubation vial. 
Vials were vortex-mixed for at least 10 seconds and immediately placed on ice. They were 
allowed to set for a minimum of 30 minutes and then centrifuged for 5 minutes at 1600 g, 4ºC 
(Universal 32R centrifuge, Hettich Zentrifugen, Tuttlingen, Germany). The supernatant (300 
mL) was transferred to new vials and the formations of both 1′-OH-MDZ and 4-OH-MDZ 
were analyzed using LC-MS. 
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2.7.2 Metabolism studies of midazolam in Supersomes® as a function of substrate 
concentration 
The aim of these experiments was to estimate and compare kinetic parameters of the 
formation of the metabolites of midazolam, 1′-OH-MDZ and 4-OH-MDZ, in two different 
recombinant microsomal preparations of CYP3A5, and with various concentrations of MDZ. 
Metabolism of midazolam in Supersomes®, with or without coexpressed cytochrome b5, was 
evaluated over a range of substrate concentrations (0.5-50 µM). Incubations were prepared as 
described in section 2.7.1. The metabolisms were initiated by addition of 50 µL of either 
Supersomes® with or without coexpressed cytochrome b5, diluted 1:64 in a buffer solution 
consisting of 10 mM HEPES, 2 mM EDTA and 0.25 M sucrose. The incubation time was 7.5 
minutes for both enzyme preparations. The analysis of the two metabolites of MDZ was 
performed using LS-MS. Velocity of the metabolism as a function of substrate concentration 
was expressed as the amount of either 1′-OH-MDZ or 4-OH-MDZ per pmol CYP3A5 protein 
per minute. Enzyme kinetic analysis of the data was preformed by nonlinear regression using 
Graphpad Prism version 4.03 (GraphPad.software, San Diego, USA). 
 
2.7.3 Preparation and isolation of microsomes from CYP3A5 transfected THLE cells 
After the thawing (section 2.3.1), the CYP3A5 transfected THLE cells were allowed to go 
through three passages. On the day before harvesting (seven days after the last splitting), the 
fresh PFMR-4 culturing medium was added to the cells. At this point confluence was 
approximately 90%. On the day of harvesting, the cells grown in 75 cm2 culturing flasks were 
suspended in 5 mL buffer solution of 0.154 M KCl and 50 mM Tris-HCl, pH 7.4. The cell 
suspension was centrifuged at 4ºC, 710 g for 5 minutes (Hettich centrifuge, Universal 32R). 
The pellet was resuspended in hypotonic (0.05 M) sucrose solution (500 µL per 12 million 
cells). Homogenisation of the cells was performed by 10 strokes with a 7 mL, tight fitting 
Dounce homogenisator. Subsequently, 445 µL of a hypertone sucrose solution (2.5 M) was 
added to make environment isotonic. The cell-suspension was stroke three more times with 
the pestle. The mixture was then centrifuged at 4ºC in three subsequent steps, 10 minutes at 
1700 g, (Hettich Zentrifugen, Universal 32R), 10 minutes at 12 000 g (Beckmann, Avanti J-
25) and 60 minutes at 105 000 g (Sorvall Ultra Pro 80), with transferral of the supernatant to 
the next step each time. After these centrifugations, the pellet, containing the microsomes, 
was homogenised in a buffer solution consisting of 10 mM HEPES, 2mM EDTA and 0.25 
mM sucrose (200 µL per 12 million cells). The microsomes suspension was stored at -70ºC. 
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2.7.4 Metabolism studies of midazolam in microsomes isolated from the CYP3A5 
transfected THLE cells 
The metabolism of midazolam was studied in the microsomes isolated from the CYP3A5 
transfected THLE cells (section 2.7.3). Incubation buffer was prepared as described in section 
2.7.1. Metabolism of midazolam was studied at three concentrations: 10, 25 and 50 µM. The 
metabolism was initialized by adding 100 µL of undiluted microsomes isolated from the 
CYP3A5 transfected cells. In addition, three vials containing only the incubation buffer and 
midazolam were used as a negative control. All the mixtures were incubated in a 37˚C 
shaking (grade 7.5) water bath for 10 minutes, when they were terminated by addition of 150 
µL ice cold ACN with 0.044 µM DIA to each incubation vial. Vials were vortex for at least 
10 seconds and immediately placed on ice. They were allowed to set for a minimum of 30 
minutes and then centrifuged for 5 minutes at 1600 g, 4ºC (Universal 32R centrifuge, Hettich 
Zentrifugen, Tuttlingen, Germany). The supernatant (300 µL) was transferred to new vials 
and the formations of both 1′-OH-MDZ and 4-OH-MDZ were analyzed using LC-MS. 
 
2.8 LC-MS 
LC-MS is high-performance liquid chromatography coupled to mass spectrometry. It is a 
highly sensitive analytical method. In the MS step, the ions of interest are selected according 
to their mass - to - charge ratio (m/z). This ion is fragmented. Separation of the analysts by 
use of HPLC precedes the MS detection. Some of the advantages of LC-MS are low detection 
limit (pg-level), short run time, high specificity, precision and accuracy.  
 
2.8.1 LC-MS analysis method  
LC-MS analysis of the hydroxylated metabolites of MDZ was performed using a method 
validated by Postvoll [58], with modifications. The hydroxylated metabolites of MDZ were 
eluated by a gradient mobile phase system containing mobile phase A (ammonium - 
concentrated formic acid - deionised water) and mobile phase B (acetonitrile - methanol) 
(section 7.1.6). A pre-run switch in duration of 3 minutes, where the mobile phase A was sent 
to waist, was added to the validated method [58], in order to eliminate sucrose interfering with 
the analysis. Analysis run time per sample was 17 minutes. The relative contribution of 
mobile phase B increased linearly from 25% to 37.5% during the first five minutes after the 
sample injection. This mobile phase mixture was held constant for 2.5 minutes. During the 
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following 2.5 minutes, the mobile phase B content was increased to 46.7% and then quickly 
to 80%.  From 11th to 17th minute, the colon was re-equilibrated by reversing the mobile phase 
B to the start concentration of 25%. Flow rate of the mobile phase was 0.5 mL/min during the 
analysis and 1 mL/min during the re-equilibration of the colon. All these steps were carried 
out before injection of the next sample. The analysis of the chromatograms of the separated 
metabolites was performed using the software LCMSsolution Version 2.05 (LabSolutions, 
Shimadzu, Japan). 
 
2.8.2 Validation of the linearity of the analysis method 
In order to test the linearity of the analysis method described in section 2.8.1, standard curves 
for 1′-OH-MDZ and 4-OH-MDZ were made. Seven concentrations of each of these two 
metabolites, ranging from 0.013-0.15 µM were analyzed, and 2 parallels of each 
concentration were measured using the LC-MS analysis method described in section 2.7.1. 
Each standard sample contained 118 mM Tris-H2SO4 (pH 7.4) buffer, 150 µL acetonitrile 
with 0.044 µM internal standard diazepam and both metabolites at their respective 
concentrations, making the total volume of 370.5 µL, equal to the volume used in metabolism 
studies, section 2.9.1. The obtained standard curves were used to calculate the amount of 
metabolites formed in the metabolism studies (section 2.7). 
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3 RESULTS 
 
3.1 STUDIES OF GENE EXPRESSION OF CYP3A5 
To study gene expression of CYP3A5, RT-PCR was performed, and the products of RT-PCR 
were separated on a 2% agarose gel (Figure 8). CYP3A5 gene has 75 base pairs (bp). Low 
molecular weight ladder was used as a reference (Figure 8). The amount of CYP3A5 cDNA 
was normalized to the amount of β-actin (housekeeping gene) cDNA in each sample (Figure 
8, lanes 5 - 7). The CYP3A5 transfected THLE cells (Figure 8, lane 3) showed gene 
expression of CYP3A5, in contrast to non-transfected THLE cells (Lane 2), where no gene 
expression of CYP3A5 was observed. This indicates that stable transfection with CYP3A5 
was successfully obtained by use of Lipofectin® Reagent under conditions described in 
section 2.5.1, Table 1, using 1 µg plasmid DNA per plate. 
                                                                                             
 
                                   
 
 
 
 
                                                                 
Å75 bp 
 
                                                                 1     2    3    4     5    6     7    Ladder 
 
Figure 8: RT-PCR products separated on a 2% agarose gel. 1: Blank sample (only CYP3A5 primers), 2: non-
transfected THLE cells (negative control), 3: CYP3A5 transfected THLE cells, 4: CYP3A5 (positive control), 5-
7: β-actin. 
 
3.2 STUDIES OF PROTEIN EXPRESSION BY WESTERN BLOTTING 
Results from protein expression studies of CYP3A5 in the transfected THLE are shown in 
Figure 9. A protein standard containing proteins with various known molecular weights was 
added to one of the wells in the gel to be used as a reference. CYP3A5 protein has a 
molecular weight of 57109 Da [31].  The bands from the insect microsomes (Figure 9, bands 
2-5) and HLM (Figure 9, band 6), which have been incubated with CYP3A5 specific 
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antibodies, were positioned approximately at the same level as the standard protein with 
molecular weight of 50 Da, showing that they were expressing CYP3A5 proteins. The bands 
for the CYP3A5 transfected THLE cells (Figure 9, bands 7-9) were positioned higher than the 
standard protein with molecular weight of 50 Da, and the bands for the CYP3A5 proteins 
from insect microsomes. This indicates that the molecular weight of the proteins expressed in 
the CYP3A5 transfected THLE cells was higher than 50 Da, and they possibly did not have 
the same form as the reference proteins (Figure 9, bands 2-6). 
 
 
 
 
                                              1      2       3     4      5     6       7       8     9 
 
Figure 9: Picture of a film developed after addition of CYP3A5 antibody. Well 1: Protein standard, wells 2-5 
contain dilutions of insect CYP3A5 microsomes with declared amounts of CYP3A5 proteins.  2: insect (i) 
CYP3A5 1:7500, 3: iCYP3A5 1:10000, 4: iCYP3A5 1:15000, 5: iCYP3A5 1:20000. Well 6: HLM. Wells 7 - 9: 
samples from CYP3A5 transfected THLE cells. Well 1 contained standard proteins, but the bands for these are 
not shown in the picture since they do not bind to CYP3A5-specific antibodies. 
 
 
3.3 METABOLISM STUDIES WITH MIDAZOLAM 
 
3.3.1 Metabolism of midazolam as a function of time 
Formation of the two metabolites of midazolam,  1′-OH-MDZ and 4-OH-MDZ, was studied 
as a function of time in CYP3A5 expressing insect microsomes (Supersomes®) (Figure 10A 
and B, respectively) and in Supersomes® with coexpressed b5 (Figure 10C and D, 
respectively), in order to assure linear conditions. Curves describing formation of 1′-OH-
MDZ at both concentrations of MDZ, 3 µM (blue) and 50 µM (red) in Supersomes® showed 
tendency of bending after approximately 10 minutes of incubation (Figure 10A). On the other 
hand, when Supersomes® coexpressed with b5 were used, formation of 1′-OH-MDZ was more 
linear with increasing incubation time, both at 3 µM and 50 µM MDZ (Figure 10C). When it 
comes to the formation of 4-OH-MDZ, curves were almost linear with time at both 
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microsomes preparations, and at both concentrations of midazolam used (Figures 10C and D). 
Based on these experiments it was concluded that incubation time of 7.5 minutes would 
assure linear conditions in the experiments of midazolam metabolism as a function of 
substrate concentration in both microsomal preparations. 
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Figure 10: Time curves showing formation of 1′-OH-MDZ (A and C) and 4-OH-MDZ (B and D) after 
incubation with 3 µM MDZ (blue) and 50 µM MDZ (red). All points represent averages of duplicate 
measurements. Figures A and B show metabolite formations in Supersomes®, while figures C and D demonstrate 
incubations in Supersomes® with coexpressed cytochrome b5. 
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3.3.2 Metabolism of midazolam in Supersomes® as a function of substrate 
concentration 
The LC-MS chromatograms of the formed metabolites, 1′-OH-MDZ and 4-OH-MDZ, were 
integrated with respect to peak height. Correlation factors from the standard curves of the 
metabolites (section 2.8.2) were used to calculate velocity of the metabolism expressed as 
pmol of either 1′-OH-MDZ or 4-OH-MDZ per pmol CYP3A5 protein per minute. Examples 
of standard curves used for these calculations are showed in Figure 11.  
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 Figure 11: Examples of standard curves for 1′-OH-MDZ (A) and 4-OH-MDZ (B) 
 
 
 
Kinetic analysis of the metabolite formation was performed using GraphPad Prism 4.03 
(GraphPad software, San Diego, CA, USA). The dose-response curves showing formation of 
1′-OH-MDZ as a function of midazolam concentration from two separate experiments in the 
two insect CYP3A5 microsomal preparations are shown in Figure 12. Both curves describing 
formation of 1′-OH-MDZ in Supersomes® without cytochrome b5 (Figures 12A and C) 
showed substrate inhibition (section 1.8); and the kinetic parameters of these reactions were 
described using the equation for uncompetitive inhibition (Equation 4). On the other hand, the 
curves observed after incubations with Supersomes® with coexpressed b5 (Figures 12B and D) 
showed Michaelis-Menten like kinetics and have a hyperbolic shape. However, non-linear 
regression gave a slightly better fit with the Hill’s equation (Equation 3) than with the 
Michaelis-Menten equation (Equation 2). 
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Figure 12: Dose-response curves showing formation of 1′-OH-MDZ Supersomes® (A and C), and in 
Supersomes® with coexpressed cytochrome b5 (B and D) Non linear regression of the analysis data was 
performed using GraphPad Prism 4.03 (GraphPad software, San Diego, USA). 
 
The estimated kinetic parameters for the formation of 1′-OH-MDZ in the two microsomal 
preparations are presented in Table 2. Vmax values were 6-fold higher in Supersomes® without 
cytochrome b5 (74.50 and 75.49 pmol 1′-OH-MDZ/pmol CYP3A5/min) compared to those 
where cytochrome b5 was coexpressed (12.39 and 13.20 pmol 1′-OH-MDZ/pmol 
CYP3A5/min). Km values were in the same range, but slightly higher in the preparations 
where cytochrome b5 was coexpressed with the CYP3A5 enzymes (2.5 µM) than in the 
Supersomes® without cytochrome b5 (1.9 µM). Consequently, the CLint values were 
approximately 7-fold higher in Supersomes® without cytochrome b5 than in those without it 
(Table 2). 
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Table 2: Kinetic data with 95 % confidence interval for the formation of 1′-OH-MDZ in two different 
microsomal preparations of CYP3A5. Data from two separate experiments for each preparation are shown. n is 
Hill’s coefficient (section 1.8, equation 3). Ksi is the coefficient describing the grade of the inhibition (section 
1.8, equation 4). U.I. is uncompetitive inhibition. 
 
Supersomes® Exp. Vmax* Km/ S50** Ksi n  CLint R2 Model 
1 74.5 (65.4-83.6) 
1.90 
(1.31-2.49) 
31.1 
(21.8-40.3)  39.2 0.967 U.I. Without 
b5
2 75.5 (57.7-93.3) 
1.98 
(0.90-3.06) 
24.2 
(12.2-36.2)  38.1 0,931 U.I. 
1 12.4 (12.0-12.8) 
2.52 
(2.04-2.99)  
1.37 
(1.17-1.57) 4.93 0.990 Hill With b5
2 13.2 (12.4-14.0) 
2.50 
(1.67-3.33)  
1.36 
(1.01- 1.71) 5.27 0.971 Hill 
*Unit is pmol 1′-OH-MDZ/pmol CYP3A5/min 
**Unit is µM 
 
 
Figure 13 shows the observed formation curves of the minor metabolite of MDZ, 4-OH-
MDZ, in the two microsomal preparations of CYP3A5, in two separate experiments. Figures 
13A and C represent metabolite formation in Supersomes® without cytochrome b5, while 
figures 13B and D represent incubations with coexpressed cytochrome b5. All of the curves 
were sigmoid (section 1.8) and were best fitted using Hill’s equation (Equation 3).  
 
The estimated kinetic parameters for the formation of 4-OH-MDZ in the two microsomal 
preparations are presented in Table 3. Values for Vmax in the microsomal preparations without 
cytochrome b5 were 8.9 and 6.9 pmol 4-OH-MDZ/pmol CYP3A5/min, while Km values were 
14.3 and 15.3 µM for the formation of 4-OH-MDZ. Greater uncertainty was associated with 
the parameters describing 4-OH-MDZ formation in the microsomal preparations with 
coexpressed cytochrome b5 (Figures 13B and D) since these curves barely reached saturation 
(Figure 13B) or, did not appear to reach it at all (Figure 13D). The estimated CLint values in 
the Supersomes® without cytochrome b5 were twice as high as those in the Supersomes® with 
coexpressed cytochrome b5 (Table 3).  
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Figure 13: Dose-response curves showing formation of 4′-OH-MDZ in insect CYP3A5 microsomes (A and C) 
and insect CYP3A5 microsomes with coexpressed  cytochrome b5 (B and D). 
    
 
Table 3: Kinetic data with 95 % confidence interval for the formation of 4-OH-MDZ in two different 
microsomal preparations of CYP3A5. Data from two separate experiments for each preparation are shown. 
 
Supersomes® Exp. Vmax* Km/ S50** N CLint R2 Model 
1 8.98 (7.25-10.7) 
14.3 
(10.1-18.4) 
1.05 
(0.80-1.29) 0.62 0.988 Hill Without 
b5
2 6.89 (6.16-7.62) 
15.3 
(8.36-22.3) 
1.38 
(1.06-1.70) 0.45 0.988 Hill 
1 4.88 (3.63-6.12) 
20.0 
(14.3-25.7) 
1.03 
(0.78-1.27) 0.24 0.990 Hill With b5
2 17.1 (-23.0-57.2) 
54.6 
(54.4-163) 
0.74 
(0.45-1.02) 0.31 0.980 Hill 
*Unit is pmol 4-OH-MDZ/pmol CYP3A5/min 
**Unit is µM 
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Figure 14 shows a formation ratio of the two midazolam metabolites (1′-OH-MDZ/4-OH-
MDZ), expressed in peak heights as a function of substrate concentration in the two 
microsomal preparations, Supersomes® with and without coexpressed cytochrome b5. Both 
preparations showed a concentration-dependent change in the ratio of the major and minor 
oxidation product, with higher 1′-OH/4-OH-MDZ product ratio at low substrate 
concentrations, and a decrease in the ratio at higher concentrations of MDZ. The difference 
between the formation ratios in the two preparations was also highest at low substrate 
concentrations, with the Supersomes® without coexpressed cytochrome b5 (red colour) 
showing higher ratio (approximately 50), compared to Supersomes® with cytochrome b5 (blue 
colour) (approximately 30). Formation ratios of the two metabolites in the two microsomal 
preparations were overlapping at higher midazolam concentrations. 
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Figure 14: Curve showing formation ratio of 1′-OH-MDZ to 4-OH-MDZ as a function of MDZ concentration in 
two Supersomes® preparations. Red colour represents 1′-OH/4-OH-MDZ ratio in the Supersomes® without 
cytochrome b5, while the blue colour represents the same ratio in the Supersomes® with cytochrome b5. The 
inserted curve shows the formation ratio in the two preparations at lower concentrations of MDZ. 
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3.3.3 Metabolism of midazolam in the CYP3A5 transfected THLE cells as a function of 
substrate concentration 
LC-MS analysis of midazolam metabolism in microsomes from CYP3A5 transfected THLE 
cells showed no formation of the two metabolites, 1′-OH-MDZ and 4-OH-MDZ. There was 
no difference between LC-MS chromatograms of the samples containing microsomes and 
those not containing microsomes. It was concluded that microsomes isolated from the 
CYP3A5 transfected THLE cells did not metabolize midazolam. 
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4 DISCUSSION 
  
4.1 METHODOLOGICAL CONSIDERATIONS 
The aim of a stable trasfection is to obtain a cell clone with the gene of interest permanently 
integrated into the genome. To achieve this, the transgene must spontaneously integrate by 
recombination of the plasmid into the host genome and replicate in synchrony with the cell. In 
this thesis, the plasmid coding for the CYP3A5 enzymes was successfully integrated into the 
genome of the THLE cells (section 3.1). However, studies of protein expression and pilot 
metabolism studies with the microsomes isolated from these cells (section 3.1 and 3.3.3, 
respectively), gave negative results. This suggests that even though the CYP3A5 DNA had 
become integrated into the genome of the THLE cells, the conditions were not optimal for 
obtaining functional CYP3A5 proteins.  
 
Efficiency of a transfection is affected by a variety of experimental conditions, which had 
been taken into account in the present thesis, and the conditions used are summarized in Table 
1. For example, the cell density at the time of transfection is an important factor, but it varies 
with different cell types. For adherent cells, such as the ones used in this thesis, confluence 
between 70-90% is recommended in order to provide high yields. Another important issue is 
the phase of the cell cycle, as the cells should not be in the stationary phase under the 
transfection. Thirdly, presence of serum (BSA) during the transfection process was once 
considered to decrease the efficiency, but now it is established that serum can be present in 
the growing medium, as performed in this thesis, as long as the DNA-lipid cationic complexes 
(section 2.4) are formed in the absence of serum, since some proteins can interfere with their 
formation. The DNA-cationic lipid ratio is also of importance, and in this thesis it was 
showed that a ratio of 5:1 results in a successful transfection.  
 
Despite the fact that the performed transfection seemed to have succeeded, the expression of 
functional CYP3A5 proteins did not occur. The quantity of the transfected CYP3A5 genes is 
uncertain and, assuming that this was low, approaches directed towards increased transfection 
efficiency, besides those summarized in Table 1, could be an alternative. Stable transfection, 
as conducted in this thesis, takes at least several weeks to perform. Cells containing integrated 
DNA are rare and must be amplified by selection for a drug resistance (blasticidin treatment, 
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section 2.5.1). However, cell line resulting after stable transfection should be a stable source 
of protein production, which yet, turned out not to be the case in this thesis, where CYP3A5 
proteins were not expressed. A potential factor which could be further evaluated in order to 
increase the efficiency of transfection is to perform transient transfection. The level of 
enzyme expression in transient expression systems is usually far higher than that obtained 
with stable systems [9]. Detection of transient expression of the transgene generally lasts for 1 
to 7 days. Only a fraction of DNA delivered to the cell makes it to the nucleus for 
transcription with eventual export of the message to the cytoplasm for protein production. 
Within a few days, most of the foreign DNA is degraded by nucleases or diluted by cell 
division, and after a week, its’ presence can no longer be detected. Less time and work is 
required to perform transient expression than stable expression, but since the efficiency of 
DNA uptake and level of expression varies from one assay to the next, experiments must be 
carefully controlled. However, considering the fact that the CYP3A5 transfected THLE cells 
did not express functional CYP3A5 proteins, transient transfection might be worth trying in 
the future. 
  
Film developed in Western analysis of the proteins expressed in the CYP3A5 transfected 
THLE cells (Figure 9) showed formation of bands after addition of the CYP3A5 antibodies. 
Since these antibodies are specific for CYP3A5, it indicates that at least protein fragments 
recognized by these antibodies are present. However, position of the bands, which is higher 
than references with declared CYP3A5 protein content, demonstrates that the molecular 
weight of the proteins from the transfected cells is higher, and they possibly do not have the 
same form as the reference proteins. Possible explanation to the higher molecular weight is 
that the appropriate post-translational modifications have not occurred. Protein synthesis is 
one of the most complex biosynthetic processes, starting with the activation of amino acids in 
the cytosol and terminating with the proteins folding to their active, three-dimensional forms. 
After synthesis, many proteins are directed to particular locations in the cell. In eukaryotic 
cells, the so called targeting signals are often bound to the polypeptides, transferring them to 
their location in the cell, ER in the case of CYP enzymes. Uncompleted protein processing 
could result with the targeting signal still being attached to the polypeptide, resulting in higher 
molecular weight. In conclusion, even though the observed results from the transfection 
indicate that the CYP3A5 gene was inserted, the reason why there was no expression of 
CYP3A5 proteins requires further evaluation. 
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4.2 CYP3A5 CATALYZED MIDAZOLAM METABOLISM 
Pharmacokinetic parameters such as bioavailability and half-life are of major importance in 
defining the pharmacological and toxicological profile of drugs, and they can be calculated 
from clearance intrinsic, obtained from in vitro studies. Extrapolations of the in vitro data to 
in vivo are highly debated and quantitative predictions of in vivo clearance have, for many 
compounds, shown to be poor in retrospective studies [59]. Recombinant CYP enzymes, as 
the ones presented in this thesis, are used for these predictions, and variations in these 
expression systems can affect the accuracy of the prediction.  
 
4.2.1 Formation of 1′-OH-MDZ in the two microsomal preparations 
One of the primary aims of the present thesis was to investigate CYP3A5 catalyzed formation 
of 1′-OH-MDZ, which is the main metabolite of midazolam, in different microsomal 
preparations. Since the CYP3A5 transfected THLE cells showed no metabolism, the 
remaining two preparations to be investigated were recombinant insect microsomes 
specifically expressing CYP3A5 enzymes; the only difference between them being the 
presence of cytochrome b5 in one of the two preparations. There are two main observations in 
the present study, both somewhat different from the previously published data. The first 
important observation is that the two preparations exerted different enzyme kinetics; 
metabolism of midazolam in microsomes with coexpressed cytochrome b5 showed Michaelis-
Menten pattern, even though the Hill’s equation gave a slightly better fit; while metabolism in 
microsomes without b5 showed substrate inhibition pattern. The fact that the two preparations 
demonstrated different kinetics suggests that cytochrome b5 might have an impact on the 
CYP3A5 catalyzed metabolism of midazolam in vitro. Substrate inhibition observed in the 
absence of cytochrome b5 is quite the opposite from previously published results [4, 29, 60], 
where midazolam metabolism in insect CYP3A5 microsomes followed classical Michaelis-
Menten kinetics, independently of the presence of cytochrome b5. The observed substrate 
inhibition in absence of cytochrome b5 is on the other hand, in accordance with the work 
published by Galetin et al. [61], where the formation of both 1′-OH-MDZ and 4-OH-MDZ 
mediated by insect CYP3A5 without cytochrome b5 demonstrated substrate inhibition. As 
mentioned in the introduction (section 1.1), substrate inhibition is a phenomenon that has 
been described previously in vitro experiments involving CYP3A enzymes, where the 
relatively large size of the active site of CYP3A enzymes with possibilities for several 
substrates binding simultaneously, has been suggested as an explanation. Effects of 
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cytochrome b5 on drug oxidation activities of several  human CYP3A enzymes have been 
investigated, and several investigators have reported enhanced enzymatic activity by addition 
of cytochrome b5 [62, 63], with CYP3A7 as an exception, where addition of cytochrome b5 
appeared to have no effect on the enzymatic activity [4]. The requirement of cytochrome b5 
for oxidations has been shown to depend on the substrates employed, but the relationship 
between chemical structures of the substrates and effects of cytochrome b5 is still not clear 
[64]. The mechanisms involved in the enhancing effect of cytochrome b5 on the CYP-
catalyzed metabolism have been extensively investigated, and donation of the second of two 
electrons in the oxidative metabolism of drugs (Figure 2) was demonstrated for the first time 
in 1971 by Hildebrandt et al. [65]. After that, several studies have shown that this donation 
prevents the oxygenated CYP complex (Figure 2) from decomposition, which is thought to 
stimulate the enzymatic effect of CYP, but increased affinity of CYP to substrates and 
enhanced activity between CYP and the reductase have also been proposed as stimulating 
effects of cytochrome b5 on CYP enzymes [66]. In 2003 Yamaori et. al. [4] investigated 14 
different CYP3A5 substrates, among them also midazolam, and reported an enhancement in 
Vmax about twice by addition of cytochrome b5, which is approximately the same 
enhancement as the one reported for CYP3A4, which has been studied more extensively with 
respect to effects of cytochrome b5 on the enzymatic activity [4].  
 
The second important observation in the present thesis is that the quantitative data describing 
the observed metabolism, somewhat surprisingly, gave lower formation rate in the 
microsomes expressing CYP3A5 with cytochrome b5. Possible explanation for the apparently 
lower formation rate in the presence of cytochrome b5 could be that the metabolic turnover 
actually is much faster, so that the formed 1′-OH-MDZ “disappears” faster, being 
subsequently metabolized during the incubation time of 7.5 minutes. As a matter of fact, a 
third minor metabolite of midazolam, the 1′,4-diOH-MDZ, has been described  previously 
[67, 68], formation of which had been observed in human liver microsomes incubated with 
both 1′-OH-MDZ and 4-OH-MDZ as substrates. On the other hand, the higher formation rate 
observed in the absence of cytochrome b5 could then be a consequence of potential 
accumulation of the formed 1′-OH-MDZ resulting from unavailability of the cytochrome b5 
that would contribute to further metabolism.  
 
Interestingly, cytochrome b5, which has been one of the main focuses of this thesis, has also 
been addressed in a study published in September 2007, where several prediction methods 
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were compared in order to determine Clint value using data from recombinant CYP enzymes, 
and which demonstrated that recombinant CYP microsomes coexpressed with cytochrome b5 
in insect cells might be suitable for use in these predictions [69].   
 
4.2.2 Formation of 4-OH-MDZ in the two microsomal preparations 
The observed formation rate for 4-OH-MDZ was slower than for 1′-OH-MDZ in the same 
microsomal preparations, which is in concordance with the previously published work [29, 
70]. On the other hand, unlike the hyperbolic formation curves reported previously [29, 70], 
the patterns of 4-OH-MDZ formation in this thesis were sigmoid. As was the case for 1′-OH-
MDZ, the reaction velocity was slightly lower when microsomes expressing cytochrome b5 
were applied, in addition to the fact that saturation was not reached.  
 
4.2.3 The relative proportions of the formation of the midazolam metabolites 
The relative ratio of the formation of the two metabolites of midazolam, 1′-OH-MDZ and 4-
OH-MDZ was also investigated. Product ratio 1′-OH/4-OH-MDZ was higher in CYP3A5 
preparation without cytochrome b5 than in the one with cytochrome b5, at low concentrations, 
while a decrease in the ratio was observed for both microsomal preparations at higher 
concentrations of midazolam. This is in concordance with the previously published results, 
where, in addition, metabolic switching to the minor metabolite has been observed at 
substrate concentrations over 50 µM MDZ [62].  For further evaluation, investigations using 
higher concentrations of midazolam would have to be performed. The observed difference in 
the formation ratio of the two metabolites at low concentrations additionally supports the 
possible impact of cytochrome b5 on the CYP3A5 catalyzed metabolism of midazolam in 
vitro. 
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4.3 FUTURE CONSIDERATIONS 
More experiments are necessary in order to characterize enzymatic activity of CYP3A5. 
THLE cells expressing specifically CYP3A5 enzymes resemble in vivo environment more 
closely than the insect cells applied in the present thesis, and studies should be carried out in 
them as well, especially since the comparison of the kinetics in these two in vitro systems has 
not been extensively studied, while there are suggestions that there might be differences in the 
metabolism of midazolam in CYP3A4 depending on the in vitro system applied [58]. In order 
to perform this comparison, the experimental conditions need to be optimalized to obtain 
functional CYP3A5 proteins following CYP3A5 transfection of the THLE cells.  
 
As the presence of cytochrome b5 appeared to be of relevance for the enzyme kinetics 
observed in this thesis, the quantification of cytochrome b5 in human liver cells using specific 
antibodies for cytochrome b5, which are commercially available, might be of importance for 
the extrapolations of the in vitro data to in vivo. Whether the expression of cytochrome b5 is 
genetically determined is another important aspect that should be addressed in the future. 
 
Performing depletion studies is also an approach that could be used to evaluate midazolam 
metabolism catalyzed by CYP3A5, as opposed to the metabolite formation method used in the 
present thesis. In the metabolite formation studies, as showed here, intrinsic clearance is 
obtained by determination of enzyme kinetic parameters (Vmax and Km). In depletion studies, 
CLint is determined by measuring the first-order rate constant for consumption of the substrate 
at a low concentration. The substrate depletion method is useful in the early drug-discovery 
stage, when the main metabolites and the metabolic pathways have not been identified. There 
are two assumptions in the depletion model that are not required if intrinsic clearance were 
determined from enzyme kinetic data (Vmax/Km), and these are: 1) the substrate concentration 
employed is well below the apparent Km, and 2) there is no significant product inhibition, nor 
is there any mechanism based inactivation of enzyme. The latter assumption might represent a 
limitation in applying depletion studies to the systems presented in this thesis, as substrate 
inhibition has been observed. However, depletion studies would be valuable in further 
investigations, especially in order to evaluate the hypothesized subsequent metabolism of 
midazolam to 1, 4-diOH-MDZ presented in this thesis. Another possibility to evaluate the 
subsequent metabolism is to include this third metabolite in the LC-MS analysis of the 
metabolite formation, which was not done in the present thesis. 
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Since genetic polymorphism is a characteristic of CYP3A5 and not CYP3A4, and these two 
enzymes are the clinically most important CYP3A enzymes, with overlapping substrate 
specificities, further studies comparing their metabolic capacities should be conducted. 
Studies of this kind have been performed, as mentioned in section 1.5.1, but there is great 
discordance in the results, which can partly be explained by the difference in enzyme 
preparations employed and how these were supplemented with coenzymes, specifically 
cytochrome b5 [62]. For example, cytochrome b5 has been coexpressed in the preparations 
with CYP3A4 and supplied in preparations with CYP3A5, and these preparations have then 
been used for comparison. Later, it has been shown that the metabolic capacity of an enzyme 
in a given preparation actually can vary dependently of the source of the cytochrome b5; with 
the preparations coexpressing it showing higher metabolic activity than preparations where 
cytochrome b5 had been supplied to the same ratio [62]. This again stresses the importance of 
standardizing in vitro systems, especially when results are to be compared across studies.  
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5 CONCLUSION 
 
The metabolism studies of midazolam in two in vitro systems, the CYP3A5 expressing 
Supersomes® with or without cytochrome b5, with respect to the formation of two 
metabolites, 1′-OH-MDZ and 4-OH-MDZ, demonstrated different kinetics depending on the 
presence of cytochrome b5. Formation of the main metabolite, 1′-OH-MDZ, demonstrated 
Michaelis-Menten like kinetics in the presence of cytochrome b5, and atypical substrate-
inhibition in the absence of cytochrome b5, while enzyme kinetic parameters calculated from 
the non-linear regression analysis showed higher formation rate of the primarily metabolites 
in the preparations without cytochrome b5 than in those with coexpressed cytochrome b5. This 
indicates that cytochrome b5 might have an impact on the CYP3A5 catalyzed metabolism of 
midazolam in vitro, but more experiments are needed to evaluate its role, in vitro as well as in 
vivo. In order to obtain expression of functional CYP3A5 proteins in the transfected THLE 
cells, the experimental conditions need to be optimalized, since this expression system will be 
of value for future comparisons of different in vitro systems. 
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7 APPENDIX 
 
7.1 RECIPES 
 
7.1.1 Solutions for culturing of THLE cells 
Trypsin-EDTA diluted with HBSS 
1:1, v/v 
Trypsin-EDTA (1x)                              25 mL 
HBSS                                                    25 Ml 
 
 
 
Growth medium 
PFMR-4 medium                                500 mL 
L-glutamine (200 mM)                        5.0 mL 
Gentamycin (10 mg/mL)                     2.5 mL 
Insulin (0.35 mM)                              2.5 mL 
Hydrocortisone (10 mM)                   0.01 mL 
EGF (5 µg/mL)                                    0.5 mL 
Transferrin (5 mg/mL)                         1.0 mL 
Triiodthyronine (1 mM)                  0.025 mL 
P/E (0.1 mM)                                       2.5 mL 
RA (3.3 µM)                                      0.05 mL 
BSA (3%)                                             50 mL 
HBSS with 2.5% FBS 
HBSS                                                 97.5 mL 
FBS                                                      2.5 mL 
 
7.1.2 Solutions for PCR analysis 
1xPBS 
10xPBS 
DEPC-dH2O 
10xPBS, Sodium citrate buffer 
NaH2PO4·H2O                                       1.57 g 
NaH2PO4·2H2O                                       9.8 g 
Na3C6H5O7·2H2O                                     60 g 
NaCl                                                      81.8 g 
Distilled H2O                                 ad 100 mL 
pH 7.4 
Autoclave 
DEPC-dH2O 
DEPC                                                      1 mL 
Distilled H2O                               ad 1000 mL 
Autoclave 
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7.1.3 Solutions for agarose gel electrophoresis 
5XTBE, Tris-borate buffer 
Tris 
HBr 
0.5 M EDTA pH 8.0 
Distilled H2O 
Autoclave 
1xTBE 
5xTBE 
Distilled H2O 
 
Ethidium bromide (10 mg/mL) 
Ethidium bromide                                0.2 mg 
Distilled H2O                                        20 mL 
Loading dye buffer  
Bromophenol blue                                 0.25 g 
Xylene cyanol FF                                  0.25 g 
Ficoll                                                        15 g 
Distilled H2O                                 ad 100 mL 
DNA standard (0.1 µg/µL) 
Low molecular weight DNA 
Ladder, 100 bp, 1 µg/µL                       20 µL 
Loading dye buffer                                33 µL 
Distilled H2O                                       147 µL 
 
 
7.1.4 Solutions for Western electrophoresis 
10% separating gel 
Distilled water                                   5.23 mL 
1.5 M Tris-HCl pH 8.8                      3.25 mL   
Monomer                                           4.33 mL 
10% SDS                                            130 µL 
10% ammoniumpersulfate (APS)         65 µL 
TEMED                                                6.5 µL 
4% stacking gel 
Distilled water                                   6.10 mL 
0.5 M Tris-HCl pH 6.8                      2.50 mL   
Monomer                                           1.30 mL 
10% SDS                                            100 µL 
10% ammoniumpersulfate (APS)         50 µL 
TEMED                                                 10 µL 
Electrophoresis buffer pH 8.3 
0.025 M Tris- HCl                                   7.5 g 
SDS                                                         2.5 g 
0.192 M Glycin                                        35 g 
Blotting buffer pH 8.3 
0.025 M Tris- HCl                                   12 g 
SDS 0.02%                                         0.8 mL    
0.192 M Glycin                                     57.6 g 
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Distilled water                                        2.5 L 20% MeOH                                        800 mL 
Distilled water                                        2.5 L 
Sample buffer 
0.5 M Tris-HCl pH 6.8                      12.5 mL 
Glycerol                                                10 mL 
10 SDS                                                  20 mL
 
2xLaemmLi buffer 
0.0625 M Tris.HCl 
0.1% SDS 
15% Glycerol  
1xLaemmLi buffer 
50% 2 X LaemmLi buffer 
50% distilled water 
T-TBS  
100 mM Tris.HCl pH 7.5 
100 mM NaCl 
0.05 % Tween  
Blotto (125 mL/membrane) 
25 g fat-free dry milk solved in  
0.5 L T-TBS. Heated, filtered and stored at 
refrigerator for about a week. 
Fixation solution 
120 mL Fix 
280 mL water 
Developing solution 
120 mL developer 
280 mL water 
 
7.1.5 Solutions for microsomal studies 
Buffer solution for microsomal studies 
200 mM Tris-H2SO4 (pH=7.4)              130 µL/vial 
20 mM MgSO4                                        5.5 µL/vial 
10 mM NADPH                                 35 µL/vial 
 
7.1.6 Solutions for LC-MS 
Mobile phase A:  
NH3 25%                                         4.036 mL 
HCOOH (conc.)                               2.125 mL 
Deionised water                               1 L 
 
Mobile phase B: 
Acetonitrile                                         950 mL 
Methanol                                               50 mL 
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7.2 RAW DATA 
 
Table 4: Peak height values for the two metabolites of MDZ (1′-OH and 4-OH) and internal standard DIA in the 
two experiments performed in Supersomes® without cytochrome b5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Experiment 1 Experiment 2 
MDZ(µM) 1-OH 4-OH DIA 1′-OH 4-OH DIA 
0.5 30212 564 18786 24975 522 18875 
1 54205 1432 19646 45094 1097 19045 
2 73748 2921 18804 76979 2768 18081 
3 90675 4814 17796 87949 5038 19270 
4 96825 6376 17953 92685 6870 18348 
5 97702 8077 18708 86741 7302 17039 
6 93440 8367 18104 89330 8756 16626 
8 98917 11876 18091 88866 11463 24511 
10 98917 11876 18091 80266 12366 18312 
12.5 92967 12701 18179 82291 13932 17258 
15 92316 13595 16792 77845 15322 18438 
20 86427 15640 18610 70001 16173 19055 
25 69167 16757 17029 66207 17555 17866 
30 70657 19538 16964 65984 19188 17333 
40 61891 20211 17774 60808 20149 18353 
50 61034 22552 18658 56417 19473 19268 
 
 
Table 5: Peak height values for the two metabolites of MDZ (1′-OH and 4-OH) and internal standard DIA in the 
two experiments performed in Supersomes® with coexpressed cytochrome b5. 
 
 Experiment 1 Experiment 2 
MDZ(µM) 1′-OH 4-OH DIA 1′-OH 4-OH DIA 
0.5 9732 0 36779 11557 370 34585 
1 18641 864 33636 20271 868 34159 
2 29374 1889 31564 32033 1860 31007 
3 38090 3324 30199 44044 3722 34392 
4 44682 4767 31545 45604 3998 32681 
5 45672 5564 29417 52144 5865 32894 
6 47712 6442 31328 57425 7761 33835 
8 52425 8637 29759 57083 8506 29774 
10 50950 9604 30168 62151 10222 32408 
12.5 50027 10679 27677 55496 10199 31421 
15 52414 11908 29393 64014 12597 31419 
20 55274 13739 31458 60770 13322 31159 
25 55708 14373 29890 63353 15832 31842 
30 61699 16815 32284 59329 16507 32999 
40 58665 17571 29460 60595 20775 31714 
50 64845 23892 34580 71024 26281 32703 
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